A new MDA grant will defray travel costs for participants in a large-scale trial to find the optimal corticosteroid regimen for boys with Duchenne MD
Robert Griggs, a professor of neurology at the University of Rochester (N.Y.), has received an MDA grant of $237,316 over three years to support travel costs for North American participants in a large, multinational trial to determine which corticosteroid treatment regimen is best for children with Duchenne muscular dystrophy (DMD).
In kindergarten, Mo Gerhardt played tee ball and soccer, and while his hand-eye coordination was excellent, his strength wasn’t.
Matthew (“Mo”) Gerhardt of Bath, Mich., will be 36 years old this fall.
MDA grant will support a study of prednisone in 25 boys with Duchenne muscular dystrophy who are less than 2½ years old
Pediatric neurologist Anne Connolly has received an MDA grant to study the effects of prednisone on Duchenne muscular dystrophy in very young children.
MDA has awarded a grant to Anne Connolly, a pediatric neurologist at Washington University in St.
Yearlong, MDA-supported study comparing two prednisone dosing schedules in Duchenne MD found similar benefits and side effects
A one-year, MDA-supported study comparing a weekend-only prednisone treatment schedule with a daily prednisone schedule in boys with Duchenne muscular dystrophy (DMD) has found that the two treatment regimens provide about the same benefits and have approximately the same side-effect profile.
A report on drug development in neuromuscular diseases as of January 2009
In the era of molecular biology, the drug development process has moved from a “let’s try it and see what happens” approach to a scientifically based process of discovery and application.
For many of the diseases in MDA’s program, drug discovery begins with gene discovery — identifying a gene that, when flawed, causes a disease.
Corticosteroids are useful treatments for some neuromuscular diseases, but finding the right medication and dosing schedule isn't always smooth sailing
Corticosteroids (also known as glucocorticoids) that are commonly used to treat neuromuscular disorders include prednisone, prednisolone and deflazacort. All are powerful medications that suppress the immune system and decrease inflammation.
Trial or Study
4 trials used prednisone in high doses ranging from 1.5 mg/kg/day to 5 mg/kg on alternate days
prolongation of walking by about 2 years in one study; one study showed no benefit